AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11988199 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 47
Study 11988199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with surgically corrected TGA
Number of subjects: 47
Study 11988199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with congenitally corrected TGA
Number of subjects: 47
Study 11988199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with subpulmonic right ventricles
Number of subjects: 47
Study 9859856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch Sleep Disorders Questionnaire (SDQ)
Number of subjects: 145
Study 7488484 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg kg‐1
Number of subjects: 20
Study 7488484 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 20
Study 2012453 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dosage zidovudine (1200 mg/d)
Number of subjects: 86
Study 2012453 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dosage zidovudine (600 mg/d)
Number of subjects: 86
Study 2012453 — intervention group
Group type: COMPARATOR
Intervention: No dosage change
Number of subjects: 86
Study 7258744 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination drug product containing triprolidine and pseudoephedrine
Number of subjects: 0
Study 7258744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31430763 — intervention group
Group type: EXPERIMENTAL
Intervention: 670 nm red light treatment (15 min daily until 34 weeks corrected age, 9 J/cm2)
Number of subjects: 86
Study 31430763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no red light)
Number of subjects: 86
Study 31779461 — intervention group
Group type: EXPERIMENTAL
Intervention: Scharioth macular lens (SML) implantation with transcranial electrical stimulation (tES)
Number of subjects: 20
Study 31779461 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 20
Study 29037354 — intervention group
Group type: EXPERIMENTAL
Intervention: HP802‐247 (allogeneic living cell therapy consisting of growth‐arrested human keratinocytes and fibroblasts)
Number of subjects: 716
Study 29037354 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with compression bandaging (control)
Number of subjects: 716
Study 26930375 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 72
Study 26930375 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A (BoNT‐A)
Number of subjects: 72
Study 24681712 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 6854
Study 24681712 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive surgery
Number of subjects: 6854
Study 24681712 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 6854
Study 24681712 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy and laparoscopic cases
Number of subjects: 6854
Study 24681712 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI)
Number of subjects: 6854
Study 22316314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (average daily dose 10,200 IU)
Number of subjects: 80
Study 22316314 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D supplementation (average daily dose 200 IU)
Number of subjects: 80
Study 22316314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 80
Study 22316314 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D supplementation
Number of subjects: 80
Study 19174529 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 182
Study 19174529 — intervention group
Group type: COMPARATOR
Intervention: Usual specialist care
Number of subjects: 182
Study 17804033 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass filtered random dot kinematograms (RDKs)
Number of subjects: 0
Study 17804033 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered random dot kinematograms (RDKs)
Number of subjects: 0
Study 17804033 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 0
Study 15101856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine-HCl 5 mg ml(-1)
Number of subjects: 90
Study 15101856 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine-HCl 5 mg ml(-1)
Number of subjects: 90
Study 15101856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-HCl 5 mg ml(-1)
Number of subjects: 90
Study 15101856 — intervention group
Group type: COMPARATOR
Intervention: All groups (Ropivacaine, Levobupivacaine, Bupivacaine)
Number of subjects: 90
Study 12221843 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus carbon dioxide baths
Number of subjects: 63
Study 12221843 — intervention group
Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 63
Study 9818665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid (HA; Hyalgan) 20 mg each for 5 weekly injections
Number of subjects: 495
Study 9818665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid (HA; Hyalgan)
Number of subjects: 495
Study 9818665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 9818665 — intervention group
Group type: COMPARATOR
Intervention: Oral naproxen
Number of subjects: 495
Study 8131527 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline dry powder inhaled via Turbuhaler (2.5 mg)
Number of subjects: 68
Study 8131527 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline inhaled via CFC inhaler and Nebuhaler (2.5 mg)
Number of subjects: 68
Study 2401100 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, 4 mg bolus and 6 mg/h intravenously
Number of subjects: 11
Study 2401100 — intervention group
Group type: COMPARATOR
Intervention: Saline, administered intravenously
Number of subjects: 11
Study 2401100 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, administered intravenously
Number of subjects: 11
Study 7437134 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33‐824 (1.25 mg, i.m.)
Number of subjects: 8
Study 7437134 — intervention group
Group type: COMPARATOR
Intervention: Morphine HCL (20 mg, i.m.)
Number of subjects: 8
Study 31164707 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quarter of vitamin A
Number of subjects: 9658
Study 31164707 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quarter of vitamin E
Number of subjects: 9658
Study 31164707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A levels change from low (1.53) to high (1.95) in low BMI category
Number of subjects: 9658
Study 31164707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A levels change from low (1.53) to high (1.95) in high BMI category
Number of subjects: 9658
Study 27910088 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (GON blockade administered four times, once per week)
Number of subjects: 44
Study 27910088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, GON blockade administered four times, once per week)
Number of subjects: 44
Study 25688820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1 gram)
Number of subjects: 120
Study 25688820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24388090 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicirc disposable instrument plus tissue adhesive
Number of subjects: 150
Study 24388090 — intervention group
Group type: COMPARATOR
Intervention: Open surgical circumcision with suturing
Number of subjects: 150
Study 21867389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 61
Study 21867389 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (HCT)
Number of subjects: 61
Study 19154853 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklets
Number of subjects: 0
Study 19154853 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 17142002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast RPLC-UV method for tenoxicam assay
Number of subjects: 0
Study 17142002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioanalytical study of tenoxicam
Number of subjects: 0
Study 15167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prompting of diabetes care
Number of subjects: 40
Study 15167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Home glucose records in computer‐assisted insulin dose adjustment
Number of subjects: 40
Study 15167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket‐sized insulin dosage computers
Number of subjects: 40
Study 15167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized educational programs
Number of subjects: 40
Study 15167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted interventions
Number of subjects: 40
Study 11283424 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group (WG): restrict energy intake by 500 kcal x d(‐1) and exercise for 45 min x d(‐1), 4 d x wk(‐1)
Number of subjects: 0
Study 11283424 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group (WG)
Number of subjects: 0
Study 11283424 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 9484382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 60 mg
Number of subjects: 41
Study 9484382 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 50 mg plus promethazine 25 mg
Number of subjects: 41
Study 9484382 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 41
Study 8045501 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal splenorenal shunting
Number of subjects: 94
Study 8045501 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization with splenectomy
Number of subjects: 94
Study 8045501 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunting
Number of subjects: 94
Study 8045501 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 94
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platinum‐vindesine (P‐VDS)
Number of subjects: 72
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platinum‐VP16 (P‐VP16)
Number of subjects: 72
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platinum‐vindesine (P‐VDS) with radiotherapy
Number of subjects: 72
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platinum‐VP16 (P‐VP16) with radiotherapy
Number of subjects: 72
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky score of 80% or more
Number of subjects: 72
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐week split interval
Number of subjects: 72
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 72
Study 2547622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (P‐VDS and P‐VP16)
Number of subjects: 72
Study 989370 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg haloperidol
Number of subjects: 40
Study 989370 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loxapine
Number of subjects: 40
Study 989370 — intervention group
Group type: COMPARATOR
Intervention: loxapine
Number of subjects: 40
Study 30951772 — intervention group
Group type: EXPERIMENTAL
Intervention: EXERCISE (1 hour of hard aerobic exercise)
Number of subjects: 40
Study 30951772 — intervention group
Group type: COMPARATOR
Intervention: REST (no exercise)
Number of subjects: 40
Study 27506803 — intervention group
Group type: EXPERIMENTAL
Intervention: vBloc therapy
Number of subjects: 123
Study 27506803 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 123
Study 25573655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 2397
Study 25573655 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education
Number of subjects: 2397
Study 23590647 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoprophylaxis childbirth preparation (coaching training)
Number of subjects: 762
Study 23590647 — intervention group
Group type: COMPARATOR
Intervention: Standard care antenatal preparation (no coaching training)
Number of subjects: 762
Study 21406094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and continued for 72 hours thereafter
Number of subjects: 360
Study 21406094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 21406094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 mcg twice daily
Number of subjects: 360
Study 19211261 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP pulsatile CPB (group A)
Number of subjects: 40
Study 19211261 — intervention group
Group type: COMPARATOR
Intervention: Standard linear CPB (group B)
Number of subjects: 40
Study 16890832 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled treatment interruptions
Number of subjects: 430
Study 16890832 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment
Number of subjects: 430
Study 14625204 — intervention group
Group type: COMPARATOR
Intervention: Lean men
Number of subjects: 15
Study 14625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight men
Number of subjects: 15
Study 14625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese men
Number of subjects: 15
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Model Building (MB) group
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Model Validation (MV) group
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE III score
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of pressors
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute renal failure (ARF)
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation, ARF, bronchoscopy, bacteremia, use of pressors, TIPS, never received CPR
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Source of admission, platelet transfusion, bacteremia, pneumonia, never received CPR
Number of subjects: 582
Study 11348958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation, platelet transfusion, bronchoscopy, TIPS, sepsis, never received CPR
Number of subjects: 582
Study 9205938 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 16
Study 9205938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7950501 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 94
Study 7950501 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 94
Study 3324917 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative shower with Chlorhexidine soap
Number of subjects: 1530
Study 3324917 — intervention group
Group type: COMPARATOR
Intervention: Local washing
Number of subjects: 1530
Study 3324917 — intervention group
Group type: COMPARATOR
Intervention: No washing
Number of subjects: 1530
Study 29159603 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intraperitoneal onlay mesh stripe (IPOM) in Group A
Number of subjects: 267
Study 29159603 — intervention group
Group type: COMPARATOR
Intervention: No additional mesh stripe in Group B (control)
Number of subjects: 267
Study 27070542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 27070542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24962326 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Prison buprenorphine Treatment Condition
Number of subjects: 211
Study 24342495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin at a dose of 30 IU/kg per day for three days
Number of subjects: 60
Study 24342495 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study 24342495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin treatment
Number of subjects: 60
Study 21323123 — intervention group
Group type: EXPERIMENTAL
Intervention: Good memorizers (Verbal Memory scores >110)
Number of subjects: 24
Study 21323123 — intervention group
Group type: COMPARATOR
Intervention: Normal memorizers
Number of subjects: 24
Study 17394534 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 49
Study 17394534 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 49
Study 17394534 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and Glibenclamide
Number of subjects: 49
Study 17300951 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus aspirin combined therapy
Number of subjects: 0
Study 17300951 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0
Study 14740521 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based navigation system
Number of subjects: 80
Study 14740521 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 80
Study 10965090 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line vectorcardiography (VCG) monitoring for 24 hours
Number of subjects: 150
Study 10965090 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line vectorcardiography (VCG) monitoring
Number of subjects: 150
Study 8783345 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 10 mg/kg/day (Group A)
Number of subjects: 21
Study 8783345 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 20 mg/kg/day (Group B)
Number of subjects: 21
Study 1337901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex cement
Number of subjects: 150
Study 1337901 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 150
Study 1337901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubli‐Seal
Number of subjects: 150
Study 1337901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaket
Number of subjects: 150
Study 1337901 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomethasone
Number of subjects: 150
Study 1337901 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCS
Number of subjects: 150
Study 1337901 — intervention group
Group type: COMPARATOR
Intervention: Positive control (gutta‐percha without sealing cement)
Number of subjects: 150
Study 1337901 — intervention group
Group type: COMPARATOR
Intervention: Negative control (nail varnish covering apex, root canal empty)
Number of subjects: 150
Study 3006226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acyclovir (ACV) 10 mg/kg every 8 h for 7 days
Number of subjects: 31
Study 3006226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLO)
Number of subjects: 31
Study 29113521 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 120
Study 29113521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30026000 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily)
Number of subjects: 553
Study 30026000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 30026000 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 553
Study 26865043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose, followed by 90 mg twice daily after PCI
Number of subjects: 350
Study 26865043 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose, followed by 75 mg once daily after PCI
Number of subjects: 350
Study 24196189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (SED-time)
Number of subjects: 394
Study 24196189 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 394
Study 24196189 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity energy expenditure (PAEE)
Number of subjects: 394
Study 24196189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 394
Study 22410586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 μg
Number of subjects: 69
Study 22410586 — intervention group
Group type: COMPARATOR
Intervention: TAP block with 0.5% ropivacaine 1.5 mg/kg
Number of subjects: 69
Study 20158973 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotores de salud intervention (8 health classes using the Su Corazón, Su Vida curriculum)
Number of subjects: 328
Study 20158973 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic educational materials at baseline, no further intervention)
Number of subjects: 328
Study 17650631 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (Aspharma Co, Anzhero‐Sudzhensk)
Number of subjects: 0
Study 17650631 — intervention group
Group type: COMPARATOR
Intervention: Capoten (Bristol Myers Squibb Co.; official Russian producer, Akrikhin KhimFarmKombinat)
Number of subjects: 0
Study 17214388 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing during TKA
Number of subjects: 0
Study 17214388 — intervention group
Group type: COMPARATOR
Intervention: Non-resurfaced patellas
Number of subjects: 0
Study 14713566 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife intervention for pregnant and postnatal women
Number of subjects: 19
Study 14713566 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychotherapy
Number of subjects: 19
Study 14713566 — intervention group
Group type: COMPARATOR
Intervention: Biological interventions
Number of subjects: 19
Study 10974967 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological debriefing
Number of subjects: 0
Study 10974967 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 8839509 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene with omeprazole (high gastric pH)
Number of subjects: 12